The revolution in the fighting against KRAS-mutant cancers occurred in 2012 when a breakthrough study showed that KRAS with G12C (glycine to cysteine) substitution can be targeted by a group of small molecules that bind covalently to the substituted cysteine in the Switch-II pocket of the protein (10) (Table 1). Here, KRAS is linked to cancer.